Randomized controlled study of a novel triple nitazoxanide (NTZ)-containing therapeutic regimen versus the traditional regimen for eradication of Helicobacter pylori infection.
Mona Ah ShehataRaghda TalaatSamah SolimanHuda ElmesseriShaimaa SolimanSherief M Abd-ElsalamPublished in: Helicobacter (2017)
Nitazoxanide-containing triple therapy is a promising therapy for the first-line eradication of H. pylori. (ClinicalTrials.gov Identifier: NCT02422706).